KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Current Deferred Revenue (2016 - 2022)

Inovio Pharmaceuticals' Current Deferred Revenue history spans 13 years, with the latest figure at $9.0 million for Q2 2022.

  • For Q2 2022, Current Deferred Revenue rose 8131.27% year-over-year to $9.0 million; the TTM value through Jun 2022 reached $9.0 million, up 8131.27%, while the annual FY2021 figure was $21628.0, 53.62% down from the prior year.
  • Current Deferred Revenue for Q2 2022 was $9.0 million at Inovio Pharmaceuticals, up from $15378.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $24.1 million in Q1 2018 and bottomed at $14853.0 in Q2 2020.
  • The 5-year median for Current Deferred Revenue is $99232.0 (2019), against an average of $2.0 million.
  • The largest annual shift saw Current Deferred Revenue tumbled 99.54% in 2019 before it skyrocketed 8131.27% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.1 million in 2018, then plummeted by 91.33% to $92353.0 in 2019, then crashed by 49.51% to $46628.0 in 2020, then tumbled by 53.62% to $21628.0 in 2021, then soared by 41432.36% to $9.0 million in 2022.
  • Per Business Quant, the three most recent readings for INO's Current Deferred Revenue are $9.0 million (Q2 2022), $15378.0 (Q1 2022), and $21628.0 (Q4 2021).